New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Joint health product with UC-II launched in Spain

Joint health product with UC-II launched in Spain
UC-II joint health products hit store shelves in Europe after InterHealth received non novel food status for UC-II in 2002. 

The launch of Spain’s Sandoz Articulaciones joint health product earlier this month marks the latest finished product to supply InterHealth Nutraceuticals’ joint health ingredient, UC-II®, in Europe. Sandoz is a Novartis company.

Similar to most of the other UC-II products in Europe, Articulaciones will be marketed through the doctor channel and available in drug stores in Spain. InterHealth aims to boost its presence of UC-II in core European markets. Europe is considered one of the largest markets for supplements in the world.

“We have a large number of customers in Europe,” stated InterHealth CEO, Paul Dijkstra. “We have about 100 products launched by European companies specifically for European customers.” UC-II joint health products hit store shelves in Europe after InterHealth received non novel food status for UC-II in 2002. “In addition to our European partners, most of our U.S. customers are organized globally and we would like to expand our coordination and sales with them.”

Dijkstra cited growing global consumer demand for joint health ingredients as a key driver of UC-II’s increasing popularity in Europe. “The appeal of UC-II is its small efficacious daily dose. Consumers only need to take 40 mg once a day. Doctor’s recommend UC-II because of its efficacy.” UC-II, which is an undenatured type II collagen, has recently been shown in a randomized, double-blind, placebo-controlled study to help alleviate joint pain due to strenuous exercise in healthy subjects.

According to Dijkstra, studying active, healthy individuals broadens UC-II’s regulatory status in Europe. “The healthy subject research demonstrates InterHealth’s commitment to the scientific development and global expansion of UC-II. Top-class research is an invaluable resource supporting the growth of new and existing UC-II business in Europe and worldwide.” With the regulatory changes affecting glucosamine and chondroitin, InterHealth expects further growth of sales and UC-II product launches in Europe.

UC-II is a patented undenatured type II collagen shown in two published clinical studies to help increase joint comfort, flexibility and mobility. Just 40 mg once a day of UC-II helps support joint health. UC-II is sourced and manufactured in the United States and sold worldwide, including Europe, Asia and in South America.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.